ERCC1蛋白表达与结肠癌FOLFOX方案化疗疗效及预后相关性分析

目的：探讨晚期结肠癌癌组织中核苷酸切除修复交叉互补基因1（excisionrepaircross—complementinggenel，ERCCl）~O表达状况及其与患者临床病理特征、奥沙利铂方案化疗疗效及预后之间的关系。方法：采用免疫组化方法检测晚期结肠癌癌组织中ERCCl蛋白表达状况。结果：晚期结肠癌癌组织中ERCCl表达阳性表达率为45．1％。ERCCl蛋白的表达状况与患者的性别、年龄、肿瘤部位、分化程度及病理类型均无关（P〉0．05）。ERCCl蛋白表达阴性患者奥沙利铂方案化疗有效率为56．O％高于表达阳性患者的34．1％（P。0．037），并且接受化疗后表达阴性患者中位生存期为19个月高于表达阳性患者的14个月（P=0．016）。结论：ERCCl蛋白表达阴性的晚期结肠癌患者接受奥沙利铂方案化疗有效率较阴性患者高并有生存受益，ERCCl的表达状态可作为晚期结肠癌化疗方案的选择及预后判断的指标。

Correlation of Expressions of ERCC1 Protein in Advanced Colon Cancer with Chemotherapic Efficacy of Oxaliplatin Regiment and Prognosis

Objective： To investigate the correlations of expressions of ERCC1 protein in advanced colon cancer with chemothera- pic efficacy of oxaliplatin regimen, clinicopathologic feature and prognosis. Methods： Expressions of ERCC1 protein in the tissues of ad- vanced colon cancer was measured by immunohistochemistry test. Results： The positive rate of ERCCl protein expression was 45.1%. The expressions of ERCC1 protein were not associated with the patient＇s gender, age, the position of the tumor, differentiation degree and pathological type （P〉0.05）. The response rate of chemotherapy in ERCC1 protein negative patients was 56.0% significantly higher than the rate in ERCCI positive patients 34.1%（P=0.037）. The median survival time of ERCCI negative patients and positive patients were 19 months and 14 months respectively, and ERCCI negative patients had longer median survival time （P=0.016）. Conclusions： ERCCI nega- tive patients received oxaliplatin regimens chemotherapy have higher response rate than positive ones, and they can obtain survival ben- efit. Expressions of ERCC1 protein might be useful in the choice of chemotherapy regimes and evaluation of prognosis for patients with advanced colon cancer.